Skip to main content
SpringerLink
Log in

Polymer Drugs in the Clinical Stage

Advantages and Prospects

  • Book
  • © 2003

Overview

Editors:
  1. Hiroshi Maeda

    1. Kumamoto University School of Medicine, Kumamoto, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Alexander Kabanov

    1. University of Nebraska Medical Center, Omaha

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Kazunori Kataoka

    1. University of Tokyo, Tokyo, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  4. Teruo Okano

    1. Tokyo Women’s Medical College, Tokyo, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 519)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (13 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. Challenges in Polymer Therapeutics

    • Alexander V. Kabanov, Teruo Okano
    Pages 1-27

  3. Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS

    • Jun Fang, Tomohiro Sawa, Hiroshi Maeda
    Pages 29-49

  4. PEG-Adenosine Deaminase and PEG-Asparaginase

    • Frank F. Davis
    Pages 51-58

  5. Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C

    • Marlene W. Modi, Matthew W. Lamb, Mari Shiomi
    Pages 59-67

  6. PEG-Methioninase

    • Robert M. Hoffman
    Pages 69-79

  7. Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate

    • Jack W. Singer, Brian Baker, Peter de Vries, Anil Kumar, Scott Shaffer, Ed Vawter et al.
    Pages 81-99

  8. HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer

    • C. Matthew Peterson, Jane-Guo Shiah, Yongen Sun, Pavla KopeČKovÁ, Tamara Minko, Richard C. Straight et al.
    Pages 101-123

  9. Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer

    • Blanka ŘÍHovÁ, JiŘÍ Strohalm, KateŘIna KubÁČKovÁ, MarkÉTa JelÍNkovÁ, LaĎKa RozprimovÁ, Milada ŠÍRov Á et al.
    Pages 125-143

  10. CM-Dextran-Polyalcohol-Camptothecin Conjugate

    • Kazuhiro Inoue, Eiji Kumazawa, Hiroshi Kuga, Hiroshi Susaki, Noriko Masubuchi, Tetsuyo Kajimura
    Pages 145-153

  11. Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs

    • Nobuhiro Nishiyama, Kazunori Kataoka
    Pages 155-177

  12. An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer

    • Y. Matsumura
    Pages 178-194

  13. Polymer Conjugates for Imaging

    • Alan C. Perkins
    Pages 195-205

  14. S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics

    • Kunihiko Nakai, Ichiro Sakuma, Hiroko Togashi, Mitsuhiro Yoshioka, Takeshi Sugawara, Hiroshi Satoh et al.
    Pages 207-216

  15. Back Matter

    Pages 217-224
    Download chapter PDF
Back to top

Keywords

About this book

Proceedings of the International Symposium on Polymer Therapeutics - Recent Progress in Clinics and Future Prospects, held July 13-14, 2001, in Nara, Japan.

The technology of polymer science has developed considerably during the past half-century, and this volume describes some of the aspects of this technology that will have a great impact in the future. Among these advances, for example, are gene delivery to specific disease sites and carrier polymers that respond to a stimulus or particular environment. Cancer targeted drug delivery is another focused area of this volume because of the important nature of EPR-effect of polymer drugs in tumor. Included are discussions of as many examples as possible of polymer drugs that have achieved, or are close to clinical use. The concept of "Polymer drugs" here is limited to primarily injectable and water-soluble agents, although also covered are some drugs in micellar form or liposomes.

This book is intended for students and researchers in the field of pharmacology who have particular interests in drug delivery, targeting, and formulation, as well as for clinicians such as oncologists who are interested in the field. People who work at regulatory agencies should also be aware such that drugs with great potential are being developed and will be beneficial to many patients, as well as to health insurance agencies because of improved cost effectiveness.

Editors and Affiliations

  • Kumamoto University School of Medicine, Kumamoto, Japan

    Hiroshi Maeda

  • University of Nebraska Medical Center, Omaha

    Alexander Kabanov

  • University of Tokyo, Tokyo, Japan

    Kazunori Kataoka

  • Tokyo Women’s Medical College, Tokyo, Japan

    Teruo Okano

Bibliographic Information

  • Book Title: Polymer Drugs in the Clinical Stage

  • Book Subtitle: Advantages and Prospects

  • Editors: Hiroshi Maeda, Alexander Kabanov, Kazunori Kataoka, Teruo Okano

  • Series Title: Advances in Experimental Medicine and Biology

  • DOI: https://doi.org/10.1007/b105364

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 2003

  • Hardcover ISBN: 978-0-306-47471-2Published: 31 March 2003

  • Softcover ISBN: 978-1-4757-7840-3Published: 28 March 2013

  • eBook ISBN: 978-0-306-47932-8Published: 11 April 2006

  • Series ISSN: 0065-2598

  • Series E-ISSN: 2214-8019

  • Edition Number: 1

  • Number of Pages: VIII, 226

  • Topics: Pharmacology/Toxicology, Polymer Sciences, Medical Biochemistry, Oncology, Pharmacy

Publish with us

Policies and ethics

Back to top

Search

Navigation